Invasive aspergillosis in glucocorticoid-treated patients

References

• Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552–558
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353: 1711–1723
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828–1838
   PubMed Web of Science ®Google Scholar
• Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999; 1: 29–39
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar
• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494–503
   PubMed Web of Science ®Google Scholar
• Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079–1086
   PubMed Web of Science ®Google Scholar
• Duncan MD, Wilkes DS. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2005; 2: 449–455
   PubMedGoogle Scholar
• Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69: 617–631
   PubMed Web of Science ®Google Scholar
• Hohl TM, Feldmesser M. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot Cell 2007; 6: 1953–1963
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 11–23
   Web of Science ®Google Scholar
• Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 1985; 76: 1755–1764
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Moretti S, Perruccio K, et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 2004; 173: 7406–7415
   PubMed Web of Science ®Google Scholar
• Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001; 7: 1291–1297
   PubMed Web of Science ®Google Scholar
• Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173–182
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Essilfie-Quaye S, Kharitonov SA, Adcock IM, Barnes PJ. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest 2007; 132: 98–105
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Takahashi H, Kobayashi M, et al. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004; 21: 215–226
   PubMed Web of Science ®Google Scholar
• Lewis RE, Wiederhold NP, Chi J, et al. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun 2005; 73: 635–637
   PubMed Web of Science ®Google Scholar
• Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology 2005; 151: 1021–1032
   PubMed Web of Science ®Google Scholar
• Orciuolo E, Stanzani M, Canestraro M, et al. Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. J Leukoc Biol 2007; 82: 839–848
   PubMed Web of Science ®Google Scholar
• Stanzani M, Orciuolo E, Lewis R, et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 2005; 105: 2258–2265
   PubMed Web of Science ®Google Scholar
• Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 2008; 197: 479–486
   PubMed Web of Science ®Google Scholar
• Kupfahl C, Heinekamp T, Geginat G, et al. Deletion of the gliP gene of Aspergillus fumigatus results in loss of gliotoxin production but has no effect on virulence of the fungus in a low-dose mouse infection model. Mol Microbiol 2006; 62: 292–302
   PubMed Web of Science ®Google Scholar
• Bok JW, Chung D, Balajee SA, et al. GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun 2006; 74: 6761–6768
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005; 55: 214–222
   PubMed Web of Science ®Google Scholar
• Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007; 51: 1078–1081
   PubMedGoogle Scholar
• Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 986–989
   PubMed Web of Science ®Google Scholar
• Kojima R, Kami M, Nannya Y, et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Blood Marrow Transplan 2004; 10: 645–652
   PubMed Web of Science ®Google Scholar
• Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007; 127: 349–355
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531–540
   PubMed Web of Science ®Google Scholar
• Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928–2936
   PubMed Web of Science ®Google Scholar
• Grow WB, Moreb JS, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplan 2002; 29: 15–19
   PubMed Web of Science ®Google Scholar
• O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827–834
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–330
   PubMed Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogenic BMT recipients. Bone Marrow Transplan 1997; 19: 801–808
   PubMed Web of Science ®Google Scholar
• Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347–353
   PubMed Web of Science ®Google Scholar
• Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229–236
   PubMedGoogle Scholar
• Gustafson TL, Schaffner W, Lavely GB, et al. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230–238
   PubMed Web of Science ®Google Scholar
• Lortholary O, Ascioglu S, Moreau P, et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European organization for research and treatment of cancer. Clin Infect Dis 2000; 30: 41–46
   PubMed Web of Science ®Google Scholar
• Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Inf Dis 1994; 19(Suppl. 1)S41–S48
   Web of Science ®Google Scholar
• Leav BA, Fanburg B, Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med 2000; 343: 586
   PubMed Web of Science ®Google Scholar
• Peter E, Bakri F, Ball DM, Cheney RT, Segal BH. Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis 2002; 35: E54–E56
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33: 116–124
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373–379
   PubMed Web of Science ®Google Scholar
• Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 506–511
   PubMed Web of Science ®Google Scholar
• Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006; 25: 382–388
   PubMed Web of Science ®Google Scholar
• Torres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002; 81: 388–397
   PubMed Web of Science ®Google Scholar
• Jacobson K, Garcia R, Libshitz H, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 615–621
   PubMed Web of Science ®Google Scholar
• Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171–178
   PubMed Web of Science ®Google Scholar
• Shibuya K, Ando T, Hasegawa C, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004; 10: 138–145
   PubMedGoogle Scholar
• Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–357
   PubMed Web of Science ®Google Scholar
• Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177: 27–34
   PubMed Web of Science ®Google Scholar
• Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517–5522
   PubMed Web of Science ®Google Scholar
• Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992; 36: 977–981
   PubMed Web of Science ®Google Scholar
• Wilson E, Thorson L, Speert DP. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991; 35: 796–800
   PubMed Web of Science ®Google Scholar
• Wolf JE, Stein SH, Little KD, Abegg AL, Little JR. Amphotericin B selectively stimulates macrophages from high responder mouse strains. Immunopharmacol Immunotoxicol 1991; 13: 221–235
   PubMed Web of Science ®Google Scholar
• Stein SH, Little JR, Little KD. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell Immunol 1987; 105: 99–109
   PubMed Web of Science ®Google Scholar
• Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278: 37561–37568
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Bozza S, Montagnoli C, et al. Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Med Mycol 2005; 43(Suppl. 1)S181–188
   PubMed Web of Science ®Google Scholar
• Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459–465
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397–1403
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Roilides E, Maloukou A, et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027–1030
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 2008; 51: 147–154
   PubMed Web of Science ®Google Scholar
• Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 1974–1976
   PubMed Web of Science ®Google Scholar
• Eierman DF, Yagami M, Erme SM, et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci USA 1995; 92: 2815–2819
   PubMed Web of Science ®Google Scholar
• Eierman DF, Yagami M, Erme SM, et al. Synergistic prevention of endotoxin induced mortality in rats by PGE1 and particles. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 341–343
   PubMedGoogle Scholar
• Simitsopoulou M, Roilides E, Likartsis C, et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 1048–1054
   PubMed Web of Science ®Google Scholar
• Natarajan U, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob Agents Chemother 1997; 41: 1575–1578
   PubMed Web of Science ®Google Scholar
• Gujral S, Brummer E, Stevens DA. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J Inf Dis 1996; 174: 888–890
   PubMed Web of Science ®Google Scholar
• McElhaney-Feser GE, Raulli RE, Cihlar RL. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother 1998; 42: 2342–2346
   PubMed Web of Science ®Google Scholar
• Helmick RA, Fletcher AE, Gardner AM, et al. Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin. Antimicrob Agents Chemother 2005; 49: 1837–1843
   PubMed Web of Science ®Google Scholar
• Latge JP, Mouyna I, Tekaia F, et al. Specific molecular features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus. Med Mycol 2005; 43(Suppl. 1)S15–22
   Google Scholar
• Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50: 2214–2216
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480–1489
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echincocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333–2338
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464–1471
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39: 99–103
   PubMed Web of Science ®Google Scholar
• Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: e35
   PubMed Web of Science ®Google Scholar
• Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006; 6: 33–43
   PubMed Web of Science ®Google Scholar
• Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005; 1: e30
   PubMed Web of Science ®Google Scholar
• Lamaris, GA, Lewis, RE, Chamilos, G, , et al. Caspofungin-mediated β-Glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and Non-Aspergillus molds. J Inf Dis 2008; [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar